延安必康(002411.SZ)2019年度淨利潤降1.01%至4億元
格隆匯5月6日丨延安必康(002411.SZ)發佈2019年年度報告，實現營業收入93.28億元，同比增長10.43%；歸屬於上市公司股東的淨利潤4億元，同比下降1.01%；歸屬於上市公司股東的扣除非經常性損益的淨利潤2.46億元，同比下降19.89%；基本每股收益0.2611元，公司計劃不派發現金紅利，不送紅股，不以公積金轉增股本。
值得注意的是，經營活動產生的現金流量淨額-4.16億元，上年度為4.03億元。
目前公司的主營業務包括醫藥工業板塊、醫藥商業板塊、新能源新材料板塊以及藥物中間體(醫藥中間體、農藥中間體)板塊四大類。
公司醫藥生產板塊受到國家醫藥行業相關政策影響導致收入較去年同期有所下降，利潤較上年同期有所下降；公司醫藥商業板塊潤祥醫藥和百川醫藥，銷售收入較上年同期有所增長，已完成承諾業績，利潤貢獻較低，綜上原因公司醫藥板塊利潤較上年同期有所降低；公司新能源、新材料板塊經營情況正常，受新能源汽車行業政策調整的影響，產品六氟磷酸鋰下游客户訂單趨於穩定，銷售收入較上年同期略有增長，利潤率較上年有所提高；新材料產品高強高模聚乙烯纖維產量和銷量較上年同期有所增加，利潤較上年同期有所增加。
“製藥生產線技改搬遷項目”車間土建工程已全部完成，生產設備正處於系統調試狀態。質檢中心、污水站、鍋爐房等配套設施還處於建設階段。公用系統、設備仍在進行緊張的調試和驗證。
2019年2月份陝西必康山陽二期新建液體制劑車間、新建中藥前處理及提取車間已取得GMP認證報告，並已全部投產。陝西必康山陽三期C區片劑、硬膠囊劑產能擴充項目也在順利推進過程中，目前已完成主體建設，正在進行內外裝修工程，工藝設備已全部採購完成，部分主體設備已到達現場。
報告期內，公司藥物中間體類產品在同行業中保持了穩定的市場份額，其中三氯吡啶醇鈉和5,5-二甲基海因產品維持了較高的毛利率；新能源類產品六氟磷酸鋰經過工藝改良後質量進一步提升，在報告期初順利通過了IATF16949汽車行業質量管理體系認證審核；新材料類產品超高分子量聚乙烯纖維擴建項目順利達產，規模效益顯現，產品品質不斷優化，產品規格品類日趨全面，已經從最初單一的400D規格發展到如今的細旦、粗旦、高強、耐切割、彩色絲等上百種型號系列。此外，公司為滿足軍工方面的特殊需求還開發出J100、J200、J300以及J400四個超高強度產品牌號。後續公司將根據超高分子量聚乙烯纖維產品的特性，積極培育新興市場，拓展應用領域，進一步擴大市場規模，形成全系列、全規格種類產品線，着力打造成為超高分子量聚乙烯纖維全球專業化生產商，滿足不同客户、不同應用行業的差異化需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
